NASDAQ:ANL Adlai Nortye (ANL) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free ANL Stock Alerts $13.75 +0.29 (+2.15%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$12.03▼$13.7550-Day Range$7.11▼$14.4252-Week Range$7.11▼$19.30Volume8,145 shsAverage Volume19,540 shsMarket Capitalization$507.38 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Adlai Nortye alerts: Email Address Adlai Nortye MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.2% Upside$30.00 Price TargetShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.90) to ($2.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsMedical Sector438th out of 914 stocksPharmaceutical Preparations Industry186th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingAdlai Nortye has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdlai Nortye has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of Adlai Nortye have been sold short.Short Interest Ratio / Days to CoverAdlai Nortye has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adlai Nortye has recently decreased by 5.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdlai Nortye does not currently pay a dividend.Dividend GrowthAdlai Nortye does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANL. Previous Next 3.8 News and Social Media Coverage News SentimentAdlai Nortye has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adlai Nortye this week, compared to 2 articles on an average week.Search Interest1 people have searched for ANL on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Adlai Nortye to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adlai Nortye insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 35.21% of the stock of Adlai Nortye is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adlai Nortye are expected to grow in the coming year, from ($2.90) to ($2.41) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Adlai Nortye Stock (NASDAQ:ANL)Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.Read More ANL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANL Stock News HeadlinesApril 26, 2024 | americanbankingnews.comCantor Fitzgerald Equities Analysts Lift Earnings Estimates for Adlai Nortye Ltd. (NASDAQ:ANL)March 29, 2024 | finance.yahoo.comAdlai Nortye Ltd.'s (NASDAQ:ANL) largest shareholders are retail investors with 59% ownership, insiders own 16%April 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 29, 2024 | globenewswire.comAdlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & DevelopmentFebruary 5, 2024 | finance.yahoo.comAdlai Nortye Ltd. Announces Pricing of Initial Public OfferingFebruary 5, 2024 | finance.yahoo.comAdlai Nortye Ltd. Announces Closing of Initial Public OfferingFebruary 5, 2024 | finance.yahoo.comAdlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster AwardFebruary 5, 2024 | finance.yahoo.comAdlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCCSee More Headlines Receive ANL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANL Previous SymbolNASDAQ:ANL CUSIPN/A CIK1944552 Webwww.adlainortye.com Phone848-230-7430FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+118.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares36,900,000Free FloatN/AMarket Cap$507.38 million OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Yang Lu (Age 43)CEO & Chairman Ms. Wei Zhang (Age 33)Chief Financial Officer Dr. Kaiyang Tang (Age 60)Senior VP & Global Head of Clinical Operations Dr. Victoria Elizabeth Demby Ph.D. (Age 54)Senior VP & Global Head of Regulatory Affairs Key CompetitorsAltimmuneNASDAQ:ALTAstria TherapeuticsNASDAQ:ATXSPhibro Animal HealthNASDAQ:PAHCAnaptysBioNASDAQ:ANABArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInstitutional OwnershipCantor Fitzgerald L. P.Bought 22,644 shares on 2/15/2024Ownership: 0.109%View All Institutional Transactions ANL Stock Analysis - Frequently Asked Questions Should I buy or sell Adlai Nortye stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adlai Nortye in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANL shares. View ANL analyst ratings or view top-rated stocks. What is Adlai Nortye's stock price target for 2024? 1 brokerages have issued 1 year price objectives for Adlai Nortye's shares. Their ANL share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price. View analysts price targets for ANL or view top-rated stocks among Wall Street analysts. How have ANL shares performed in 2024? Adlai Nortye's stock was trading at $8.99 at the beginning of 2024. Since then, ANL stock has increased by 52.9% and is now trading at $13.75. View the best growth stocks for 2024 here. Are investors shorting Adlai Nortye? Adlai Nortye saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,000 shares, an increase of 42.9% from the March 15th total of 4,200 shares. Based on an average daily trading volume, of 4,900 shares, the days-to-cover ratio is currently 1.2 days. View Adlai Nortye's Short Interest. When did Adlai Nortye IPO? Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share. When did the company's lock-up period expire? Adlai Nortye's lock-up period expired on Wednesday, March 27th. Adlai Nortye had issued 2,500,000 shares in its initial public offering on September 29th. The total size of the offering was $57,500,000 based on an initial share price of $23.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period. How do I buy shares of Adlai Nortye? Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
